Slope of change in HbA_1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

ABSTRACT:

Aims

To analyse the effect of baseline glycated haemoglobin (HbA_1c) on the reduction in HbA_1c with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

Materials and methods

Using regression analyses of individual patient data from two Phase III studies, we compared the change in HbA_1c according to a unit change in baseline HbA_1c (the slope) with empagliflozin 10 mg or 25 mg vs sitagliptin (monotherapy) after 24 weeks, and with empagliflozin 25 mg vs glimepiride (as add-on to metformin) after 52 weeks.

Results

Steeper slopes of HbA1c decline were observed with empagliflozin 10 or 25 mg vs sitagliptin monotherapy at week 24. Regression analysis showed slopes of -0.59 (95% CI -0.70, -0.47),

SUBMITTER: DeFronzo RA 

PROVIDER: S-EPMC6354821 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature